Skip to main
  1. Stocks
  2. Johnson & Johnson
  3. Forecast
JNJ

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 32%
Hold 37%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson is supported by a stronger post-consumer portfolio that concentrates capital on innovative medicine and medtech, with leadership in immunology, oncology, and neurology, plus category positions in 11 of 12 medtech platforms. The company’s growth case is reinforced by strong prescription trends and launches such as Tremfya, Icotyde, Darzalex, and Spravato, while management expects competitive growth from a pipeline with five $5B-plus and 12 $1B-plus opportunities. Even with MedTech headwinds and a recent ~6% sell-off, the business still appears defensive, cash-generative, and capable of double-digit growth through the end of the decade, with FY26 revenue around $101.0bn and EPS at $11.13.

Bears say

Johnson & Johnson is facing a negative fundamental setup because lower-than-expected organic revenue growth could be driven by weaker pipeline contribution in innovative medicine, faster loss-of-exclusivity erosion, and softer MedTech uptake amid persistent competitive headwinds. In particular, Stelara is already in year two of biosimilar erosion, with full-year erosion guidance of approximately 60% intact and 1H erosion near 57%, while management also flagged lingering electrophysiology and pulsed field ablation pressure that may delay the hoped-for 2H26 MedTech recovery. Additional downside comes from M&A integration risk, litigation and settlement costs, and reduced margin discipline, with 3Q26 EPS estimated at $2.55 versus consensus of $2.81 and OpEx at $10.15bn.

JNJ has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 32% recommend Buy, 37% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

JNJ Analyst Forecast & Price Prediction

Get the latest JNJ stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in JNJ

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 19 analysts, JNJ has a Buy consensus rating as of Oct 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $270.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $270.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


JNJ Analyst Forecast & Price Prediction

Get the latest JNJ stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in JNJ

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover JNJ stock data and trends